Metabonomics Study of Chronic Gastritis and Gastric Carcinoma
1 other identifier
observational
60
1 country
1
Brief Summary
The pathogenetic mechanisms of chronic gastritis and gastric carcinoma are different. Whether metabonomics play a role in the development of chronic gastritis and gastric cancer is still a question. So the investigators want to clarify this question by this subject.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 19, 2020
CompletedStudy Start
First participant enrolled
November 1, 2020
CompletedFirst Posted
Study publicly available on registry
November 10, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2021
CompletedJanuary 20, 2021
January 1, 2021
6 months
October 19, 2020
January 17, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Metabonomic difference in patients with chronic gastritis and gastric carcinoma
1.The different levels of metabolites in gastric tissues in patients with chronic gastritis and gastric carcinoma. 2. The common change model of metabolites in gastric carcionoma compared with chronic gastritis.
six months
Secondary Outcomes (1)
Association of different metabolic substances and disease results in chronic gastritis and gastric carcinoma
six months
Study Arms (3)
Patients with chronic superficial gastritis
Patients with chronic superficial gastritis
Patients with chronic atrophic gastritis
Patients with chronic atrophic gastritis
Patients with gastric carcinoma
Patients with gastric carcinoma
Interventions
Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
Eligibility Criteria
We will enroll patients with chronic superficial gastritis, chronic atrophic gastritis or gastric carcinoma.
You may qualify if:
- Patients with chronic superficial gastritis and chronic atrophic gastritis
- Patients with gastric carcinoma
You may not qualify if:
- Patients with history of surgery
- Patients with severe heart disease,lung disease or kidney disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
2nd Affiliated Hospital, School of Medicine
Hangzhou, Zhejiang University, 310000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yuehua Han, Dr.
2nd Affiliated Hospital, School of Medicine, Zhejiang university, China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief physician
Study Record Dates
First Submitted
October 19, 2020
First Posted
November 10, 2020
Study Start
November 1, 2020
Primary Completion
April 30, 2021
Study Completion
May 31, 2021
Last Updated
January 20, 2021
Record last verified: 2021-01
Data Sharing
- IPD Sharing
- Will not share